JFG
NBIX icon

Jefferies Financial Group’s Neurocrine Biosciences NBIX Stock Holding History

Jefferies Financial Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Buy
10,630
+7,584
+249% +$1.13M 0.01% 729
2026
Q1 		$401K Sell
3,046
-42,930
-93% -$5.7M ﹤0.01% 1299
2025
Q4 		$6.52M Buy
+45,976
New +$6.66M 0.03% 431
2025
Q2 		– Sell
-4,500
Closed -$498K – 1650
2025
Q1 		$498K Buy
+4,500
New +$570K ﹤0.01% 1046
2024
Q4 		– Sell
-4,390
Closed -$506K – 1743
2024
Q3 		$506K Sell
4,390
-390
-8% -$53.5K ﹤0.01% 975
2024
Q2 		$658K Sell
4,780
-1,155
-19% -$158K 0.01% 878
2024
Q1 		$819K Sell
5,935
-691
-10% -$94.4K 0.01% 894
2023
Q4 		$873K Buy
+6,626
New +$763K 0.01% 1011
2023
Q1 		– Sell
-14,511
Closed -$1.73M – 1865
2022
Q4 		$1.73M Buy
+14,511
New +$1.7M 0.01% 704

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jefferies Financial Group's NBIX Position: Q2 2026 in Review

Jefferies Financial Group increased its Neurocrine Biosciences (NBIX) stake by 249% in Q2 2026, buying an estimated $1.13M and bringing the position to 10,630 shares worth $1.79M. The position accounts for 0.01% of the portfolio, ranked #729.

Jefferies Financial Group first reported a position in NBIX in Q4 2022 and has held it in 9 quarters since. The position peaked at $6.52M in Q4 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Jefferies Financial Group held 10,630 shares of Neurocrine Biosciences worth $1.79M as of Q2 2026.
  • Jefferies Financial Group bought 7,584 Neurocrine Biosciences shares in Q2 2026, an estimated $1.13M.
  • Neurocrine Biosciences made up 0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #729 holding.
  • Jefferies Financial Group first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 9 quarters since.
  • Jefferies Financial Group's Neurocrine Biosciences position peaked at $6.52M in Q4 2025.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.